Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CSX Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.09 (market cap $29.60B), while CSX Corporation trades at $50.15 (market cap $92.55B). The key difference: CSX Corporation is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and CSX Corporation pays a 1.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CSX | |
|---|---|---|
Market Cap | $29.60B | $92.55B |
Sector | Health | Industrials |
52-Week High | $491.22 | $53.21 |
52-Week Low | $205.48 | $32.05 |
Enterprise Value | $27.56B | $110.52B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
CSX trades at $50.08, down slightly by 0.09% today, with a neutral technical signal despite bullish moving averages. The railroad operator posted strong Q2 2026 results with EPS of $0.54 beating estimates by 4.2% and revenue growth of 10%, driving improved investor sentiment. Valuation metrics show a P/E of 29.05 and P/S of 6.41, while profitability remains solid with 22.21% net margins and 24.37% ROE. Recent news highlights volume growth and margin expansion as key catalysts.
CSX demonstrates operational strength with consecutive earnings beats and raised 2026 guidance, supported by intermodal demand and cost controls. However, declining revenue trends from $14.9B in 2022 to $14.1B in 2025 and high debt levels pose risks. Analyst consensus is bullish with a $52.57 price target (4.9% upside), though competitive pressures and fuel costs require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
